Bristol-Myers Squibb UFT
FDA's Oncologic Drugs Advisory Committee will review Bristol's NDA for UFT capsules (tegafur/uracil) in combination with leucovorin calcium tablets for the first-line treatment of metastatic colorectal cancer on Sept. 16. Bristol's NDA for Orzel (UFT packaged with leucovorin calcium tablets) for the same indication will not be reviewed by the committee (1"The Pink Sheet" Aug. 9, In Brief). The two NDAs contain identical clinical data and were submitted simultaneously. Leucovorin is marketed by several manufacturers
Learn what's happening at the US FDA. On the go.
More from Archive
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.